Kelly Bree, M.D.

Peer-Reviewed Articles

1. Sood A, Rudzinski JK, Labbate CV, Hensley PJ, Bree KK, Guo CC, Alhalabi O, Campbell MT, Siefker-Radtke AO, Navai N, Dinney CPN, Gao J, Kamat AM. Long-term Oncological Outcomes in Patients Diagnosed with Non-metastatic Plasmacytoid Variant of Bladder Cancer: A 20-year University of Texas MD Anderson Cancer Center Experience. J Urol 211(2):241-255, 2024. e-Pub 2023. PMID: 37922370.
2. Contieri R, Tan WS, Grajales V, Hensley PJ, Martini A, Bree K, Myers A, Nogueras-Gonzalez G, Navai N, Dinney CP, Guo C, Kamat AM. Influence of Lamina Propria Invasion Extension on T1 High-grade Non-muscle-invasive Bladder Cancer in Patients Undergoing BCG or Radical Cystectomy. BJU Int. e-Pub 2024. PMID: 38374533.
3. Contieri R, Grajales V, Tan WS, Martini A, Sood A, Hensley P, Bree K, Lobo N, Nogueras-Gonzalez GM, Guo CC, Navai N, Dinney CP, Kamat AM. Impact of Age >70 Years on Oncological Outcomes in Patients with Non-Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guerin. BJU Int 133(1):63-70, 2024. e-Pub 2023. PMID: 37442564.
4. Lobo N, Duan Z, Sood A, Tan WS, Grajales V, Contieri R, Lindskrog SV, Dyrskjøt L, Zhao H, Giordano SH, Williams SB, Bree KK, Kamat AM. Association of Age with Non-muscle-invasive Bladder Cancer: Unearthing a Biological Basis for Epidemiological Disparities?. Eur Urol Oncol. e-Pub 2024. PMID: 38302322.
5. Contieri R, Hensley PJ, Tan WS, Grajales V, Bree K, Nogueras-Gonzalez GM, Lee BH, Navai N, Dinney CP, Kamat AM. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. Eur Urol Oncol 6(6):590-596, 2023. e-Pub 2023. PMID: 37558542.
6. Tan WS, McElree IM, Davaro F, Steinberg RL, Bree K, Navai N, Dinney CP, O'Donnell MA, Li R, Kamat AM, Packiam VT. Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol 6(5):531-534, 2023. e-Pub 2023. PMID: 37468392.
7. Bree KK, Kokorovic A, Westerman ME, Hensley PJ, Brooks NA, Qiao W, Shen Y, Kamat AM, Dinney CP, Navai N. Repeat Transurethral Resection of Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but not Therapeutic. Reply. J Urol 210(2):101097JU0000000000003553, 2023. e-Pub 2023. PMID: 37211780.
8. Tan WS, Grajales V, Contieri R, Hensley P, Bree K, Msaouel P, Guo CC, Nogueras-Gonzalez GM, Navai N, Dinney CP, Kamat AM. Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin-unresponsive Non-Muscle-Invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes. Eur Urol Open Sci 13(53):16-22, 2023. e-Pub 2023. PMID: 37441349.
9. Wang XS, Bree KK, Navai N, Kamal M, Shen SE, Letona E, Cleeland CS, Shi Q, Gottumukkala V. Utility of Patient-Reported Symptom and Functional Outcomes to Indicate Recovery after First 90 Days of Radical Cystectomy: A Longitudinal Study. Cancers (Basel) 15(11), 2023. e-Pub 2023. PMID: 37297013.
10. Tan WS, Grajales V, Bree K, Li R, Nogueras-Gonzalez GM, Navai N, Dinney C, Kamat AM. Bacillus Calmette-Guérin (BCG) Unresponsive Non-Muscle-Invasive Bladder Cancer: Are the Subgroups Equal?. BJU Int. e-Pub 2023. PMID: 37246493.
11. Hensley PJ, Duan Z, Bree K, Sood A, Zhao H, Lobo N, Contieri R, Campbell MT, Guo CC, Navai N, Williams SB, Dinney CP, Kamat AM. Competing Mortality Risk from Second Primary Malignancy in Bladder Cancer Patients following Radical Cystectomy: Implications for Survivorship. Urol Oncol 41(2):108.e11-108.e17, 2023. e-Pub 2022. PMID: 36404232.
12. Hensley PJ, Duan Z, Bree K, Sood A, Zhao H, Lobo N, Contieri R, Campbell MT, Guo CC, Navai N, Williams SB, Dinney CP, Kamat AM. Competing Mortality Risk for Second Primary Malignancy in Bladder Cancer Patients Following Radical Cystectomy: Implications for Survivorship. Urol Oncol 41(2):108e11-108.317, 2023. PMID: 36404232.
13. Faulk A, Avulova S, Bree KK, Baak-Kukreja J, Westerman ME. Pelvic Organ Preservation in Non-muscle Invasive Bladder Cancer: Less is More. Eur Urol Focus S2405-4569(23):00103-7, 2023.
14. Wang XS, Bree KK, Navai N, Kamal M, Shen S-E, Letona E, Cleland CS, Shi Q, Gottumukkala V. Utility of Patient-reported Symptom and Functional Outcomes to Indicate Recovery after First 90 Days of Radical Cystectomy: A Longitudinal Study. Cancers 15(11):3051, 2023.
15. Hensley PJ, Bree KK, Guo CC, Lobo N, Campbell MT, Pettaway CA, Kamat AM. Clinicopathological Analysis and Outcomes of Inflammatory Myofibroblastic Tumours of the Urinary Bladder. BJU Int 130(5):604-610, 2022. e-Pub 2021. PMID: 34773684.
16. Hensley PJ, Duan Z, Bree K, Sood A, Zhao H, Lobo N, Contieri R, Campbell MT, Guo CC, Navai N, Williams SB, Dinney CP, Kamat AM. Competing Mortality Risk from Secondary Primary Malignancy in Bladder Cancer Patients following Radical Cystectomy: Implications for Survivorship. Urol Oncol S1078-2439(22):00393-3. e-Pub 2022. PMID: 36404232.
17. Westerman ME, Bree KK, Msaouel P, Kukreja JB, Mantaring C, Rukundo I, Gonzalez MG, Gregg JR, Casteel KN, Matin SF. Apixaban vs Enoxaparin for Post-Surgical Extended-Duration Venous Thromboembolic Event Prophylaxis: A Prospective Quality Improvement Study. J Urol 208(4):886-895, 2022. e-Pub 2022. PMID: 36082549.
18. Lobo N, Hensley PJ, Bree KK, Nogueras-Gonzalez GM, Navai N, Dinney CP, Kamat AM. Should Patients with Non-Muscle-Invasive Bladder Cancer Discontinue Fibrin Clot Inhibitors during Bacille Calmette-Guérin?. BJU Int 130(4):463-469, 2022. e-Pub 2021. PMID: 34854189.
19. Lobo N, Bree KK, Hensley PJ, Nogueras-Gonzalez GM, Abraham P, Navai N, Dinney CP, Kamat AM. Reduced-dose Bacillus Calmette-Guérin (BCG) in an Era of BCG Shortage: Real-world Experience from a Tertiary Cancer Centre. BJU Int 130(3):323-330, 2022. e-Pub 2021. PMID: 34847263.
20. Escott M, Avulova S, Bree K, Westerman ME. Radical Cystectomy and Women's Sexual Health - Can we do Better?. Curr Opin Urol 32(5):545-553, 2022. PMID: 35916011.
21. Bree KK, Hensley PJ, Lobo N, Brooks NA, Nogueras-Gonzalez GM, Guo CC, Navai N, Grossman HB, Dinney CP, Kamat AM. All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guérin Response in High-Grade Ta Tumors. J Urol 208(2):284-291, 2022. e-Pub 2022. PMID: 35770498.
22. Kamal M, Navai N, Bree KK, Williams LA, Cleeland CS, Shen SE, Wang XS.. Validation and Application of MD Anderson Symptom Inventory Module for Patients with Bladder Cancer in the Perioperative Setting. Cancers (Basel) 16(14):3896, 2022. PMID: 36010890.
23. Hensley PJ, Bree KK, Brooks N, Matulay J, Li R, Nogueras-Gonzalez GM, Nagaraju S, Navai N, Grossman HB, Dinney CP, Kamat AM. Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes. Eur Urol Oncol 5(3):347-356, 2022. e-Pub 2021. PMID: 33935020.
24. Bree KK, Hensley PJ, Pettaway CA. Germline Mutations in African American Men with Prostate Cancer: Incidence, Implications and Diagnostic Disparities. Urology 163:148-155, 2022. e-Pub 2021. PMID: 34453957.
25. Bree KK, Shan Y, Hensley PJ, Lobo N, Hu C, Tyler DS, Chamie K, Kamat AM, Williams SB. Management, Surveillance Patterns, and Costs Associated with Low-Grade Papillary Stage Ta Non-Muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013. JAMA Netw Open 5(3):e223050, 2022. e-Pub 2022. PMID: 35302627.
26. Bree KK, Navai N. Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy. Reply. J Urol 207(2):476-477, 2022. e-Pub 2021. PMID: 34694162.
27. Lobo N, Hensley PJ, Bree KK, Nogueras-Gonzalez GM, Navai N, Dinney CP, Sylvester RJ, Kamat AM. Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin. Eur Urol Oncol 5(1):84-91, 2022. e-Pub 2021. PMID: 34920986.
28. Hensely PJ, Lobo N. Bree KK, Tan WS, Gontero P, Williams SB, Guo CG, Giannarini G, Dyrskjot L, Kamat AM. Predictive Biomarkers in the Management of Bladder Cancer: Perspective in an Evolving Therapeutic Landscape. Societe Internationale d'Urologie Journal 3(4):245-257, 2021.
29. Bree KK, Hensley PJ, Brooks N, Matulay J, Nogueras-Gonzalez GM, Navai N, Dinney CP, Kamat AM. Impact of Sex on Response to BCG in Non-Muscle Invasive Bladder Cancer Patients: A Contemporary Review from a Tertiary Care Center. World J Urol 39(11):4143-4149, 2021. e-Pub 2021. PMID: 34117914.
30. Bree KK, Hensley PJ, Brooks NA, Matulay J, Li R, Nogueras Gonzalez GM, Navai N, Grossman HB, Matin SF, Dinney CPN, Kamat AM. Impact of Upper Tract Urothelial Carcinoma on Response to BCG in Patients with Non-Muscle-Invasive Bladder Cancer. BJU Int 128(5):568-574, 2021. e-Pub 2021. PMID: 33484074.
31. Hensley PJ, Bree KK, Brooks N, Matulay J, Li R, Nogueras González GM, Navai N, Grossman HB, Dinney CP, Kamat AM. Time Interval from Transurethral Resection of Bladder Tumour to Bacille Calmette-Guérin Induction does not Impact Therapeutic Response. BJU Int 128(5):634-641, 2021. e-Pub 2021. PMID: 33783950.
32. Hensley PJ, Bree KK, Campbell MT, Alhalabi O, Kokorovic A, Miest T, Nogueras-Gonzalez GM, Gao J, Siefker-Radtke AO, Guo CC, Navai N, Dinney CP, Kamat AM. Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. J Urol 206(5):1258-1267, 2021. e-Pub 2021. PMID: 34184926.
33. Westerman ME, Bree KK, Kokorovic A, Frank J, Wang XS, Kamat AM, Dinney CPN, Navai N. What Women Want: Radical Cystectomy and Perioperative Sexual Function Educational Needs. Urology 157:181-187, 2021. e-Pub 2021. PMID: 34186127.
34. Hensley PJ, Bree KK, Campbell MT, Alhalabi O, Kokorovic A, Miest T, Nogueras-Gonzalez GM, Gao J, Siefker-Radtke AO, Guo CC, Navai N, Dinney CP, Kamat AM. Reply by Authors. J Urol 206(5):1267, 2021. e-Pub 2021. PMID: 34372685.
35. Bree KK, Hensley PJ, Westerman ME, Kokorovic A, Nogueras-Gonzalez GM, Dinney CP, Kamat AM, Navai N. Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy. J Urol 206(3):577-585, 2021. e-Pub 2021. PMID: 33872050.
36. Gaylis F, Bree KK, Dato P, Andriole GL, Kane CJ, Kader AK. Low Penetrance Germline Genetic Testing: Role for Risk Stratification in Prostate Cancer Screening and Examples from Clinical Practice. Rev Urol 22(4):152-158, 2020. PMID: 33927572.
37. Patel SH, Panian J. Bree K, Derweesh I, Millard F, Randall J, McKay R. Systemic Treatment of Bone Disease in Metastatic Urinary Malignancies. Eur Urol Focus 6(1):17-25, 2020. e-Pub 2020.
38. Panizzon MS, Bree K, Hsieh C, Hauger R, Xian H, Jacobson K, Lyons MJ, Franz CE. Genetic Variation in the Androgen Receptor Modifies the Association between Testosterone and Vitality in Middle-aged Men. J Sex Med 17(12):2351-2361, 2020.
39. Ghali F, Elbakry AA, Hamilton ZA, Yik K, Nassrei R, Patel S, Eldefrawy A, Ryan S, Bradshaw AW, Meagher M, Bree K, Reddy M, Lee HJ, Derweesh IH. Robotic Partial Nephrectomy for Clinical T2a Renal Mass is Associated with Improved Trifecta Outcome Compared to Open Partial Nephrectomy: A Single Surgeon Comparative Analysis. World J Urol 38(5):1113-1122, 2020.
40. Ryan ST, Nguyen V, Bree KK, Holst DD, Kader AK. Germline Genetics in Localized Prostate Cancer. Curr Opin Urol 29(4):326-333, 2019. PMID: 31116139.

Manuals, Teaching Aids, Other Teaching Publications

1. Bree KK, Whicker SA, Fromme HB, Paik S and Greenberg L. What Can Programs Learn from the Literature When Starting a New or Refining an Established Curriculum. Residents as Teachers (RAT), 2014.

Book Chapters

1. Bree KK, Santiago-Lastra Y. Diabetic Cystopathy. In: Urologic Care for Patients with Progressive Neurological Conditions. Springer, 159-166, 2019.